Hom Dennis 4
4 · Sagimet Biosciences Inc. · Filed Jul 20, 2023
Insider Transaction Report
Form 4
Hom Dennis
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-07-18+9,286→ 9,286 totalExercise: $6.36Exp: 2029-04-27→ Series A Common Stock (9,286 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−136,846→ 0 totalExercise: $6.36Exp: 2031-01-26→ Common Stock (136,846 underlying) - Award
Stock Option (Right to Buy)
2023-07-18+111,438→ 111,438 totalExercise: $6.36Exp: 2029-04-27→ Series A Common Stock (111,438 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−9,286→ 0 totalExercise: $6.36Exp: 2029-04-27→ Common Stock (9,286 underlying) - Award
Stock Option (Right to Buy)
2023-07-18+136,846→ 136,846 totalExercise: $6.36Exp: 2031-01-26→ Series A Common Stock (136,846 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−111,438→ 0 totalExercise: $6.36Exp: 2029-04-27→ Common Stock (111,438 underlying)
Footnotes (3)
- [F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- [F2]The shares underlying this option are fully vested and exercisable as of the date hereof.
- [F3]The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.